200,000+ products from a single source!
sales@angenechem.com
145514-04-1 | 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-
CAS No: 145514-04-1 Catalog No: AG001D4P MDL No:
Product Description
Catalog Number:
AG001D4P
Chemical Name:
1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-
CAS Number:
145514-04-1
Molecular Formula:
C9H12N6O3
Molecular Weight:
252.2300
IUPAC Name:
[(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
InChI:
InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1
InChI Key:
RLAHNGKRJJEIJL-RFZPGFLSSA-N
SMILES:
OC[C@@H]1OC[C@@H](O1)n1cnc2c1nc(N)nc2N
UNII:
54I81H0M9C
Properties
Complexity:
308
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
2
Defined Bond Stereocenter Count:
0
Exact Mass:
252.097g/mol
Formal Charge:
0
Heavy Atom Count:
18
Hydrogen Bond Acceptor Count:
8
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
252.234g/mol
Monoisotopic Mass:
252.097g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
134A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1.2
Literature
| Title | Journal |
|---|---|
| Antiretroviral drugs: critical issues and recent advances. | Indian journal of pharmacology 20120101 |
| Recent advances in antiretroviral drugs. | Expert opinion on pharmacotherapy 20110101 |
| New trends in nucleoside biotechnology. | Acta naturae 20100701 |
| Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. | Analytical chemistry 20100301 |
| Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. | PloS one 20100101 |
| Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. | Antiviral therapy 20100101 |
| Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. | AIDS (London, England) 20071001 |
| Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. | Antiviral research 20070901 |
| Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| [Advances in the study of nucleoside antiviral drugs]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060801 |
| Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). | Antiviral therapy 20060101 |
| Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. | AIDS (London, England) 20051014 |
| New targets and new drugs in the treatment of HIV. | Enfermedades infecciosas y microbiologia clinica 20050701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine. | Antimicrobial agents and chemotherapy 20050501 |
| Emerging anti-HIV drugs. | Expert opinion on emerging drugs 20050501 |
| Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases. | Biochemical pharmacology 20041101 |
| In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 20041101 |
| New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. | Current opinion in pharmacology 20041001 |
| HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. | The international journal of biochemistry & cell biology 20040901 |
| Antiviral therapy: nucleotide and nucleoside analogs. | Clinics in liver disease 20040501 |
| Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. | Current topics in medicinal chemistry 20040101 |
| Synthesis of (-)-DAPD. | Nucleosides, nucleotides & nucleic acids 20040101 |
| Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro. | Antimicrobial agents and chemotherapy 20031101 |
| Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. | Antimicrobial agents and chemotherapy 20030601 |
| Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. | The Journal of biological chemistry 20030523 |
| [Antiretroviral therapy 2003. The current status]. | MMW Fortschritte der Medizin 20030428 |
| New antiretroviral drugs. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20030301 |
| Gateways to clinical trials. March 2003. | Methods and findings in experimental and clinical pharmacology 20030301 |
| In vitro activity of potential anti-poxvirus agents. | Antiviral research 20030101 |
| Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. | Hepatology (Baltimore, Md.) 20020901 |
| Highlights in the development of new antiviral agents. | Mini reviews in medicinal chemistry 20020401 |
| Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. | Antimicrobial agents and chemotherapy 20020301 |
| Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach. | Antiviral chemistry & chemotherapy 20020301 |
| Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. | Journal of acquired immune deficiency syndromes (1999) 20020101 |
| In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. | Antimicrobial agents and chemotherapy 20010901 |
| DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories). | Current opinion in investigational drugs (London, England : 2000) 20010301 |
| Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. | Antimicrobial agents and chemotherapy 20010101 |
| Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. | Antiviral research 20001101 |
| In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. | Antimicrobial agents and chemotherapy 20000701 |
| Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. | Antimicrobial agents and chemotherapy 19991001 |
| Perspectives for the treatment of hepatitis B virus infections. | International journal of antimicrobial agents 19990701 |
| Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. | Nucleosides & nucleotides 19990101 |
| 1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. | Journal of medicinal chemistry 19930108 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.